Modeling the Intersection of Tau and Ab in Alzheimer Disease
About the Research Project
Program
Award Type
Standard
Award Amount
$300,000
Active Dates
July 01, 2011 - June 30, 2014
Grant ID
A2011086
Co-Principal Investigator(s)
Teresa Gomez-Isla, MD, PhD, Massachusetts General Hospital
Goals
Alzheimer disease starts with neurofibrillary lesions in a special brain area, the entorhinal cortex, which is responsible for memory related brain functions. We propose to make a model of this stage of the disease by genetically engineering a mouse to develop these same lesions in only this brain area; doing so will allow us to study the earliest phase of the disease, and to learn about whether early lesions lead to disease progression.
Summary
The entorhinal cortex is the part of the brain that is responsible for communications to and from the hippocampus (which, in turn, is the part of the brain that’s important for creating and maintaining memories). In Alzheimer’s disease, brain lesions tend to start in the entorhinal cortex and “spread” to other parts, with devastating effects. One of the lesions formed in Alzheimer’s are called “tangles” that contain tau protein. Drs. Bradley Hyman, Teresa Gomez‐Isla, and colleagues will study how Alzheimer’s affects the entorhinal complex and how the lesions spread from this initial place of damage to other parts of the brain. They will create and study a new mouse model of Alzheimer’s where tau protein is directed to be expressed only in the entorhinal cortex. Amyloid, the other key molecule in Alzheimer’s affects the connections between neurons that originate in the entorhinal cortex. Other mouse models don’t address the spread of lesions, but this model is designed to isolate this key part of progression to later stages of Alzheimer’s. In the future, this model could then be used for testing treatments to halt the spread of the lesions, and the interaction of lesions, before they cause cell damage and death in other parts of the brain.
Grants
Related Grants
Alzheimer's Disease Research
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Alzheimer's Disease Research
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Alzheimer's Disease Research
Advancing the Promising Cerebroprotectant AST-004 to Human Clinical Trials
Active Dates
July 02, 2021 - June 30, 2024
Principal Investigator
William Korinek, PhD
Advancing the Promising Cerebroprotectant AST-004 to Human Clinical Trials
Active Dates
July 02, 2021 - June 30, 2024
Principal Investigator
William Korinek, PhD